A large-scale study of 1,446 patients with acute leukemias has found no significant difference in survival after transplant using unmanipulated haploidentical grafts vs. unrelated cord blood grafts. Patients had ALL (n=528) or de novo AML (n=918), and the median follow-up time was 24 months. Additional results indicate no differences between the two graft choices in relapse incidence, non-relapse mortality, and leukemia-free survival. Unrelated cord blood transplantation was associated with higher graft failure and delayed engraftment in both AML and ALL recipients. The researchers concluded that “both approaches are valid for acute leukemia patients lacking an HLA-matched donor and both strategies expand the donor pool for patients in need.”
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Comparable Outcomes in Haploidentical, Unrelated Cord Blood HCT
Jun 2015